Browsing by Subject "Genitourinary tumors"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Editorial: Emerging Biomarkers in Genitourinary Tumors
    (Frontiers, 2019-04-26) Montironi, Rodolfo; Santoni, Matteo; Cimadamore, Alessia; Lopez-Beltran, Antonio; Cheng, Liang; Pathology and Laboratory Medicine, School of Medicine
  • Thumbnail Image
    Item
    Role of STAT3 pathway in genitourinary tumors
    (Future Science Group, 2015-11-01) Santoni, Matteo; Conti, Alessandro; Piva, Francesco; Massari, Francesco; Ciccarese, Chiara; Burattini, Luciano; Cheng, Liang; Lopez-Beltran, Antonio; Scarpelli, Marina; Santini, Daniele; Tortora, Giampaolo; Cascinu, Stefano; Montironi, Rodolfo; Department of Pathology and Laboratory Medicine, IU School of Medicine
    The STAT3 is often dysregulated in genitourinary tumors. In prostate cancer, STAT3 activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial-mesenchymal transition. In addition, STAT3 promotes the progression from carcinoma in situ to invasive bladder cancer and modulates renal cell carcinoma angiogenesis by increasing the expression of HIF1α and VEGF. STAT3 is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer. In this review, we describe the role of STAT3 in genitourinary tumors, thus describing its potential for future therapeutic strategies.